CESCAIL - Capsule Endoscopy delivery at SCale through enhanced AI anaLysis

CESCAIL - 通过增强的人工智能分析在 SCale 进行胶囊内窥镜检查

• 批准号: 830236
• 金额: $ 70.11万
• 依托单位: CORPORATEHEALTH INTERNATIONAL UK LTD
• 依托单位国家: 英国
• 项目类别: Innovation Loans
• 财政年份: 2021
• 资助国家: 英国
• 起止时间: 2021 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=830236
• 关键词: CESCAIL; Capsule; Endoscopy; delivery; SCale

Our aim is to help eradicate bowel cancer and improve treatment for a wide range of gastrointestinal diseases through integrated solutions for prevention, early detection, and diagnosis.CorporateHealth International's (CHI) primary product is a tele-endoscopy managed service: Capsule Endoscopy (CE) to visualise the bowel with a swallowable camera and provide a full evaluation to determine bowel cancer risk, diagnose GI symptoms, and precisely decide on optimal follow-up -- if any. This service can be delivered in any setting, from outpatient to self-administration.Currently, CHI is the single service provider for NHS Scotland in a partnership with the CE manufacturer Medtronic, and only commercial company to offer this managed service across Europe. NHS England is evaluating their approach to deploy CE, potentially offering CHI a broad market entry.Video analysis is a resource-intensive process, relying on expert nurses and doctors that inspect up to 400,000 images for suspicious findings in a 2-stage process taking up to 2 hours for a high-quality report.Artificial Intelligence (AI) holds the promise that this process can be made much more efficient while increasing overall accuracy.CHI is in a unique position to create Machine Learning (ML) data for a Neural Network-based AI solution as well as to have the organizational flexibility to make use of that AI within our operational environment.Since January 2019, CHI has been partnering with multiple companies, academics, and NHS organizations in the Innovate UK-sponsored project AID-GI to develop such an AI system.AID-GI concludes February 28, 2021 with a prototype, ready to be used alongside standard operations.Our project is therefore looking to leverage the prototype to conduct all necessary clinical trials for certification, harden the software to achieve medical device Class IIa status and further improve the breadth and accuracy of the AI system.The outcome should then be an AI-led process that reduces the average video analysis time to under 30 minutes. In turn that reduces resource requirements to make a truly large-scale service possible. What would take 100 weeks to recruit to address the UK market opportunity, can then be done in 10 weeks.

我们的目标是通过预防、早期检测和诊断的综合解决方案，帮助根除肠癌，并改善各种胃肠道疾病的治疗。CorporateHealth International（CHI）的主要产品是远程内窥镜管理服务：胶囊式内窥镜（CE）通过可吞咽的摄像头可视化肠道，并提供全面评估，以确定肠癌风险，诊断GI症状，并精确地决定最佳的后续行动--如果有的话。这项服务可以在任何环境下提供，从门诊到自我管理。目前，CHI是苏格兰NHS与CE制造商Medtronic合作的唯一服务提供商，也是唯一一家在欧洲提供这种托管服务的商业公司。NHS英格兰正在评估他们的方法来部署CE，可能提供CHI一个广泛的市场进入。视频分析是一个资源密集型的过程，依赖于专家护士和医生，检查多达400，在2个阶段的过程中，最多需要2个小时才能生成高质量的报告。人工智能（AI）CHI在为神经网络创建机器学习（ML）数据方面处于独特的地位-基于人工智能的解决方案，以及有组织的灵活性，以利用我们的运营环境中的人工智能。自2019年1月以来，CHI一直与多家公司，学者，和NHS组织在创新英国赞助的项目AID-GI开发这样的人工智能系统。AID-GI结束2021年2月28日的原型，准备与标准操作一起使用。因此，我们的项目希望利用原型进行所有必要的临床试验，认证，强化软件以达到IIa类医疗器械状态，并进一步提高人工智能系统的广度和准确性。结果应该是人工智能主导的过程，将平均视频分析时间减少到30分钟以下。这反过来又减少了资源需求，使真正的大规模服务成为可能。什么将需要100周的招聘，以解决英国市场的机会，然后可以在10周内完成。